Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006; 12(11 Pt 1):3394-401.
Sandler HM "The Best Treatment of Locally Advanced Prostate Cancer is: Radiation Therapy and Hormones", Debate participant, First CURy Congress, Barcelona, February 2, 2008.
Sandler HM Invited panelist, Public Forum, ASCO-ASTRO-SUO Genitourinary Cancer Symposium, February 13, 2008.
Sandler HM "Radiation Therapy: How Much Androgen Deprivation Therapy is Enough?" ASCO-ASTRO-SUO Genitourinary Cancer Symposium, San Francisco, February 14, 2008.
Sandler HM "Prostate Cancer Update" and "Bladder Cancer/Testicular Cancer Update", ASTRO Spring Refresher Course, Houston, April 4, 2008.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters L, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT: HRQOL and satisfaction with cancer treatment outcome from the perspective of early stage prostate cancer patients and their spouse/partners. NEJM 358:1250-1261, 2008.
Soto DE, Glaser S, Roberts RH, Schipper MJ, McLaughlin PW, Ray ME, Sandler HM, Pan CC: Impact of pelvic field size and common iliac nodal coverage on treatment outcomes in localized prostate cancer. Urology 71:313-317, 2008.
Lee IH, Sadetsky N, Carroll P, Sandler HM: The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. J Urol 179:1072-1076, 2008.
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton H, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU: Ten-Year Follow-Up Of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. JCO 26:2497-2504, 2008.
Spencer BA, Miller DC, Litwin MS, Ritchey JD, Stewart AK, Dunn RL, Gay EG, Sandler HM, Wei JT. Variations in quality of care for men with early-stage prostate cancer. JCO 26:3735-3742, 2008.
Soto DE, Andridge RR, Pan CC, Williams SG, Taylor JMG, Sandler HM: In patients experiencing biochemical failure after radiation therapy pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure free interval. Int J Radiat Oncol Biol Phys 71:1295-1301, 2008
Khor L-Y, Bae K, DeSilvio M, Al-Saleem T, Hammond MEH, Grignon DJ, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A: Protein kinase A RI-alpha (PKA-RIa) predicts prostate cancer outcome: An analysis of Radiation Therapy Oncology Group Trial 86-10. Int J Radiat Oncol Biol Phys 71:1309-1315, 2008.
Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM: Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of Radiation Therapy Oncology Group Protocol 9413. Urology 2008.
Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU: Diabetes and mortality in men with locally advanced prostate cancer: Analyses of Radiation Therapy Oncology Group (RTOG) Protocol 92-02. JCO 26:4333-4339, 2008.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urology 26:2497-2504, 2008.
Lee I, Sandler HM: Hormone therapy and radiotherapy for intermediate risk prostate cancer. Semin Radiat Oncol 181:7-14, 2008.
Oh K, Sandler HM: Second malignancies after radiation therapy for prostate cancer: Keeping perspective. Point-Counterpoint. Urology 72:971-3, 2008.
Sandler HM. Prostate cancer matters. Issue guest editor. Semin Radiat Oncol. 18:1, 2008
Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P; Hereditary Breast Cancer Study Group; Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, Mckinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C. Rapid progression of prostate cancer in men with a BRCA2 mutation. BR J Cancer. 2008 Jul 22;99(2):371-4.